BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Teva Pharma GmbH submitted on 10 October 2003 an application for Marketing 
Authorisation to the European Medicines Agency (EMEA) for AZILECT, through the centralised 
procedure. After agreement by the CHMP on 25 April 2003, this medicinal product has been referred 
to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Prof. Cristina Sampaio   
Co-Rapporteur: Dr. David Lyons 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 18 November 1999. The Scientific 
Advice pertained to clinical aspects of the dossier. 
Licensing status: 
A new application was filed in the following countries: USA. 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 27 October 2003. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 14 January 
2004  (Annex  1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 12 January 2004 (Annex 2). 
During  the  meeting  on  24-26  February  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions  was sent to the 
applicant on  26 February 2004 (Annex 3). 
The applicant submitted the responses to the CHMP consolidated List of Questions on 19 April 
2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  25 May 2004 (Annex 4). 
During  the  CHMP  meeting  on  22-24  June  2004,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant (Annex 5). 
The  applicant  submitted  the  written  responses  to  the  CHMP  consolidated  List  of  Outstanding 
issues on 08 September 2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 1st October 2004 (Annex 6). 
During the CHMP  meeting  on  19-21 October 2004, outstanding issues  were addressed by the 
applicant during an oral explanation before the CHMP. 
During  the  meeting  on  16-18  November  2004,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  to  AZILECT  on  18  November  2004.  The  applicant 
provided the letter of  undertaking  on the  follow-up  measures to be  fulfilled post-authorisation 
on 16 November 2004 (Annex 7). 
1/1 

EMEA 2005 
 
